Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
All-In with Chamath, Jason, Sacks & Friedberg Podcast Recap
Published:
Duration: 30 min
Guests: Dave Ricks
Summary
Eli Lilly's CEO, Dave Ricks, discussed the company's substantial growth driven by GLP-1 drugs, including a new pill matching the efficacy of injectables, and addressed issues like counterfeit drugs and high patient costs. The episode also explored the broader biotech industry's funding challenges,...
What Happened
Eli Lilly's CEO, Dave Ricks, discussed the company's significant growth under his leadership, with a market capitalization increase of about 860% and a stock price surge of over 1000%. This growth is partly attributed to the development of GLP-1 drugs, including a new pill that performs as well as its injectable counterpart.
Tirzepatide, branded as Manjaro, has become the best-selling drug globally, surpassing Keytruda and generating $8.1 billion in revenue with an 80% growth rate. Eli Lilly has been addressing challenges such as counterfeit drugs in China and high out-of-pocket costs for patients, reducing these costs from $1,000 to $499, with plans for further reduction as oral versions become available.
Eli Lilly is heavily investing in research and development, spending 25% of its sales, approximately $14.2 billion, on R&D. The company is also constructing six new plants in the US, which will create 20,000 construction jobs and 6,000 manufacturing jobs, reflecting its commitment to innovation and growth.
The episode also touched upon the broader biotech industry, where funding has dropped significantly from $20 billion to $5 billion annually. This decline is partly due to competition from AI and other industries, while China is increasing its investment in biotech, often engaging in patent hacking.
Eli Lilly is exploring the unexpected benefits of GLP-1 drugs, which have shown effects such as smoking cessation and reduced gambling. The company is initiating studies on bipolar disorder and major depressive disorder using a new GLP-1 drug, aiming to address the substantial global burden of brain diseases.
The discussion highlighted concerns about the American food system's impact on metabolic health, emphasizing the role of processed foods. Dave Ricks also discussed the potential benefits of reducing drug advertising and reallocating those funds to R&D.
The role of PBMs (Pharmacy Benefit Managers) was examined, with a focus on their shift from improving service to prioritizing self-benefit. Mark Cuban is scheduled to discuss this topic further in an upcoming episode, as PBMs continue to be a contentious issue in the pharmaceutical industry.
Key Insights
- Eli Lilly's market capitalization increased by 860% under CEO Dave Ricks, with stock prices soaring by over 1000%. This remarkable growth is largely driven by innovations in GLP-1 drugs, including a new oral version that matches the efficacy of injected treatments.
- Tirzepatide, known commercially as Manjaro, has become the world's top-selling drug, overtaking Keytruda with $8.1 billion in revenue and an 80% growth rate. Eli Lilly's strategies to address counterfeit drugs and reduce patient costs are crucial in maintaining this momentum.
- Eli Lilly dedicates 25% of its sales to research and development, amounting to $14.2 billion. This investment supports the construction of six new manufacturing plants in the US, creating thousands of jobs and reinforcing the company's commitment to innovation.
- GLP-1 drugs have shown unexpected benefits, such as aiding smoking cessation and reducing gambling. Eli Lilly is leveraging these findings to explore treatments for bipolar disorder and major depressive disorder, addressing a significant portion of global human suffering attributed to brain diseases.
View all All-In with Chamath, Jason, Sacks & Friedberg recaps